Scholars Central

Conference abstractPublished 14 Jun 2018

Design synthesis and biological evaluation of fibrate analogues as PPAR agonists

Authors: Letizia Giampietro

University "G. d'Annunzio", Italy

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Peroxisome Proliferator-Activated Receptors (PPARs) are nuclear hormone receptors expressed in metabolically active tissues. To date, three isoforms namely PPARÃ?±, PPARÃ?³ and PPARÃ?´ are identified; they are important in lipid metabolism and glucose homeostasis. Dual PPARÃ?±/Ã?³ agonists are able to reduce side effects of selective PPARÃ?± or PPARÃ?³ agonists and may be used in dyslipidemia and type 2 diabetes mellitus simultaneously. Furthermore, PPARÃ?±/Ã?³/Ã?´ pan-agonists could alter carbohydrate and lipid metabolism in a coordinated manner. In the last years, PPARs are emerging as promising pharmacological targets also for the treatment of neurodegenerative diseases. Fibrate analogues active as PPAR agonists have, as typical pharmacophore, a carboxylic acid head and an aromatic ring with or without various spacers. In the past, we reported different fibrate analogues with good activation of PPARs. One of the best compounds was a selective PPARÃ?³ agonist GL516 (EC50=0.8 Ã?¼M). This molecule was a potential neuroprotective agent because proved effective in restoring catalase activity reducing reactive oxygen species (ROS) production and decreasing the apoptosis. Another promising molecule was a dual PPARÃ?±/Ã?³ agonist GL479 (Ã?±EC50=0.6Ã?¼M and Ã?³EC50=1.4Ã?¼M). This compound was crystallized with the PPARÃ?± and PPARÃ?³ to understand that it occupies the ligand-binding pocket of PPARÃ?± and PPARÃ?³ in two distinct conformations. In view of these promising results, and in order to gain more insight on the structure-activity relationships, we synthesized new GL479 analogues with different substituents in para to the phenyldiazenyl moiety and with the oxygen of the linker in para to the 2-methyl-2-phenoxypropanoic group. Moreover, to investigate how the azo linker modification influences the activity we synthesized nitro, amino, ureidic, amide and sulfonamide derivatives. All compounds were tested on PPARs and the results showed that some of these are promising candidates to develop new more potent PPAR agonists potentially active as neuroprotective agents. Recent Publications 1. Den Broeder MJ, Kopylova VA, Kamminga LM and Legler L (2015). Zebrafish as a model to study the role of peroxisome proliferating-activated receptors in adipogenesis and obesity. PPAR Res. 358029. 3. Giampietro L, DâÂ?Â?Angelo L, Giancristofaro A, Ammazzalorso A, De Filippis B, Fantacuzzi M, Linciano P, Maccallini C and Amoroso R (2012) Synthesis and structureâÂ?Â?activity relationships of fibrate-based analogues inside PPARs. Bioorg. Med. Chem. Lett. 22:7662-7666.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Medicinal Chemistry.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMedicinal Chemistry
  • SubjectChemistry
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Letizia Giampietro”